About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘oncology retractions’ Category

Former UT-Southwestern cancer researchers faked data in 10 papers: ORI

with 14 comments

ut southwesternThe Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what appeared to be an unrelated case.

Takao Takahashi and Makato Suzuki, both former postdocs at a cancer research center at UT-Southwestern, both “knowingly, intentionally, and recklessly falsified data” in a total of 10 papers, according to the ORI. Takahashi, now at Gifu University in Japan, was responsible for fakery in four papers, while Suzuki, now at Kumamoto University Hospital, also in Japan, falsified data in six.

We reported on the retraction of the four Takahashi papers, and one of the Suzuki papers, in November 2012. At that time, Adi Gazdar, the head of the lab where the researchers worked, told us that
Read the rest of this entry »

About these ads

Written by Ivan Oransky

September 18, 2014 at 7:58 am

Fudged figures sink breast cancer paper

with 22 comments

oncogeneA prestigious cancer journal has pulled an article over “concerns” regarding some of the figures, which PubPeer commenters had tagged as suspect.

A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.

Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »

Cancer researcher has correction upgraded to retraction

with 11 comments

mol endo coverRakesh Kumar, a researcher with six recent corrections and one retraction, has had one of those corrections upgraded to a retraction.

Here’s the unhelpful notice, from Molecular Endocrinology: Read the rest of this entry »

“Our jaws hit the floor!!” Researchers say authors doctored images for rebuttal letter

with 7 comments

eurourologyTry to follow along on this one. We think it’s worth it.

The authors of a letter replying to a comment in a urology journal have retracted their response because it contained inappropriate figures. At least, that’s the official story.

The original paper, “Effect of a Risk-stratified Grade of Nerve-sparing Technique on Early Return of Continence After Robot-assisted Laparoscopic Radical Prostatectomy,” came from a group at Weill Medical College of Cornell University led by Ashutosh Tewari. Published in July 2012 in European Urology, it purported to find that: Read the rest of this entry »

MD Anderson postdoc faked results of Novartis anti-cancer compound study

with 35 comments

jun fu

Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).

Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:

Read the rest of this entry »

Written by Ivan Oransky

August 1, 2014 at 8:00 am

UT-Southwestern cancer research group notches ninth retraction

with one comment

lung cancerA research team at the University of Texas-Southwestern that has retracted eight papers for image manipulation has retracted another, this one in Lung Cancer.

Here’s the notice for “Aberrant methylation of Reprimo in lung cancer,” published by Adi Gazdar’s group: Read the rest of this entry »

Paper about widely touted but unapproved “cure” for cancer, autism retracted

with 11 comments

int j cancerA paper about a protein being used — unapproved by health agencies — to treat diseases including cancer and autism has been retracted.

Here’s the notice from the International Journal of Cancer about a 2007 paper purporting to show that the substance, GcMAF, is useful against breast cancer: Read the rest of this entry »

Follow

Get every new post delivered to your Inbox.

Join 35,051 other followers